Neurocrine Biosciences
NBIX
#1542
Rank
A$17.28 B
Marketcap
$173.36
Share price
-0.07%
Change (1 day)
-19.22%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2023 (TTM): $2.98

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is $3.12. In 2022 the company made an earnings per share (EPS) of $2.56 an increase over its 2021 EPS that were of $1.51.

EPS history for Neurocrine Biosciences from 1997 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$2.9816.31%
2022$2.5669.47%
2021$1.51-78.21%
2020$6.93990%
2019$0.6481.82%
2018$0.35-113.5%
2017-$2.590.62%
2016-$2.5857.28%
2015-$1.6425.61%
2014-$1.3018.84%
2013-$1.10-1085.71%
2012$0.11-89.71%
2011$1.08-500%
2010-$0.27-86.92%
2009-$2.07-43.48%
2008-$3.66-57.8%
2007-$8.6792.58%
2006-$4.50371.67%
2005-$0.95-52.76%
2004-$2.0236.56%
2003-$1.48-70%
2002-$4.93118.31%
2001-$2.268.4%
2000-$2.0848.86%
1999-$1.40-20%
1998-$1.75-479.31%
1997$0.46

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$3.32 6.63%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.87-71.94%๐Ÿ‡ฌ๐Ÿ‡ง UK
-$4.71-251.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$8.64 177.00%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.85 87.79%๐Ÿ‡บ๐Ÿ‡ธ USA
$2.96-5.10%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.75-123.98%๐Ÿ‡บ๐Ÿ‡ธ USA
-$4.82-254.59%๐Ÿ‡บ๐Ÿ‡ธ USA